U.S. markets closed

IntriCon Corporation (IIN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
24.82+0.48 (+1.97%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Previous Close24.34
Open24.48
Bid24.83 x 1100
Ask24.94 x 1200
Day's Range24.48 - 25.67
52 Week Range9.95 - 28.16
Volume42,594
Avg. Volume48,524
Market Cap223.344M
Beta (5Y Monthly)1.37
PE Ratio (TTM)N/A
EPS (TTM)-0.28
Earnings DateFeb 25, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateSep 12, 2001
1y Target Est29.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • TTDKY vs. IIN: Which Stock Should Value Investors Buy Now?
    Zacks

    TTDKY vs. IIN: Which Stock Should Value Investors Buy Now?

    TTDKY vs. IIN: Which Stock Is the Better Value Option?

  • Intricon Appoints Kathleen Pepski to its Board of Directors
    GlobeNewswire

    Intricon Appoints Kathleen Pepski to its Board of Directors

    ARDEN HILLS, Minn., March 22, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ: IIN), an international company engaged in designing, developing, engineering, and manufacturing miniature interventional, implantable and body-worn medical devices, today announced the appointment of Kathleen Pepski to the company’s Board of Directors, effective March 19, 2021. “We are delighted to welcome Kathleen to Intricon and our board of directors,” said Scott Longval, President and Chief Executive Officer of Intricon. “Kathleen is a well-respected business leader in Minneapolis whose background in manufacturing and distribution, as well as mergers and acquisitions, will be instrumental in our long-term growth strategy.” Ms. Pepski’s career includes more than 30 years of finance and accounting experience at several manufacturing and distribution companies. Most recently she served as the Vice President, CFO and Treasurer at Hawkins, Inc. Her career includes executive and VP level positions with companies such as PNA Holdings, Hoffman Enclosures, BMC Industries, Inc., and The Valspar Corporation. She has more than 25 years of experience working with boards of publicly held companies as the top finance or accounting executive. She is currently serving on the board of Lakewood Cemetery Association and previously served on the boards of Delta Dental Benefit Plans of MN and The Bergquist Company. Ms. Pepski’s experience also includes executing several M&A deals as well as being a lead advisor for strategic planning, annual operating plans, and capital allocation matters. “It is a pleasure to welcome Kathleen Pepski to our board of directors,” said Philip I. Smith, Intricon’s Chairman of the Board. “I am confident that with her background and wide-ranging business experiences, Ms. Pepski will provide a valuable perspective to execute our long-term strategy and build value for the Intricon shareholder base.” “I am very excited to join Intricon, a company with a strong foundation and significant growth opportunities ahead,” said Ms. Pepski. “My background aligns very well with the Intricon mission and I am looking forward to advising on future innovation at the forefront of the miniature medical device market.” About Intricon CorporationIntricon is a Joint Development Manufacturer that integrates components and assemblies to advance micro-medical technology across a range of device platforms for global customers. Intricon approaches each engagement with an all-in commitment, working with customers every step of the way- from the earliest idea stages to ongoing production - in order to advance program performance and deliver results. With a focus on key device platforms, Intricon helps advance clinical outcomes by always looking ahead with proactive support and resources through integration of its core competencies. Intricon has facilities in the United States, Asia and Europe. The company's common stock trades under the symbol "IIN" on the NASDAQ Global Market. Investor Relations Contact:Leigh Salvo(415) 937-5404investorrelations@intricon.com

  • Benzinga

    IntriCon: Q4 Earnings Insights

    Shares of IntriCon (NASDAQ:IIN) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 50.00% year over year to $0.12, which beat the estimate of $0.04. Revenue of $30,301,000 rose by 9.41% year over year, which beat the estimate of $27,350,000. Outlook Earnings guidance hasn't been issued by the company for now. Revenue guidance hasn't been issued by the company for now. How To Listen To The Conference Call Date: Feb 25, 2021 View more earnings on IIN Time: 05:00 PM ET Webcast URL: https://edge.media-server.com/mmc/p/y6bpms6j Technicals 52-week high: $23.18 52-week low: $9.84 Price action over last quarter: Up 45.46% Company Description IntriCon Corp design, develop and manufacture miniature and micro-miniature body-worn medical and electronics products. The company has two operating segments, the Body-Worn Device segment (consisting of three markets: medical, hearing health, and professional audio), and the Hearing Health Direct-to-Consumer segment. Its primary geographic markets are the United States, Europe, Asia, and all other countries. The company serves a diverse range of markets including the hearing healthcare market, the medical biotelemetry market, and the professional audio communication market. See more from BenzingaClick here for options trades from BenzingaRecap: James River Gr Hldgs Q4 EarningsNatera: Q4 Earnings Insights© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.